A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case–control study

BMC Cardiovascular Disorders

Samy Suissa⁴  Christel Renoux²  David Langleben³  Teresa A Simon⁵  Sophie Dell’Aniello²  Laurent Azoulay¹ 

[1]Department of Oncology, McGill University, Montreal, Quebec, Canada

[2]Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, 3755 Côte-Sainte-Catherine, H-461, Montreal, Quebec, Canada, H3T 1E2

[3]Division of Cardiology, Jewish General Hospital, Montreal, Quebec, Canada

[4]Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

[5]Bristol-Myers Squibb, New Jersey, NJ, USA

关键词: net clinical benefit;    aspirin;    warfarin;    intracranial hemorrhage;    stroke;    Atrial fibrillation;   

Others  :  1084804
DOI  :  10.1186/1471-2261-12-49

 received in 2012-02-24, accepted in 2012-06-13,  发布年份 2012

【 摘 要 】

Background

As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF).

Methods

A population-based cohort study of all patients at least 18 years of age with a first-ever diagnosis of chronic AF during the period 1993–2008 was conducted within the United Kingdom General Practice Research Database. A nested case–control analysis was conducted to estimate the risk of ischemic stroke and intracranial hemorrhage associated with the use of warfarin and aspirin. Cases were matched up to 10 controls on age, sex, and date of cohort entry. The adjusted net clinical benefit of warfarin and aspirin (expressed as the number of strokes prevented per 100 persons per year) was calculated by subtracting the ischemic stroke rate (prevented by therapy) from the intracranial hemorrhage (ICH) rate (increased by therapy).

Results

The cohort included 70,766 patients newly-diagnosed with chronic AF, of whom 5519 experienced an ischemic stroke and 689 an ICH during follow-up. The adjusted net clinical benefit of warfarin was 0.59 (95% CI: 0.45, 0.73). However, the benefit was not seen for patients below (0.08, 95%: -0.38, 0.54) and above (−0.49, 95% CI: -1.13, 0.15) therapeutic range. The net clinical benefit of warfarin, apparent after 3 months of continuous use, increased as a function of CHADS₂ score. The net clinical benefit was not significant with aspirin (−0.07, 95% CI: -0.22, 0.08), though it was seen in certain subgroups.

Conclusions

Warfarin provides a net clinical benefit in patients with atrial fibrillation, which is maintained with longer duration of use, particularly when used within therapeutic range. A similar net effect is not as clear with aspirin.

【 授权许可】

   
2012 Azoulay et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006, 8:651-745.
• [2]: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
• [3]Albers GW, Sherman DG, Gress DR, Paulseth JE, Petersen P: Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol 1991, 30:511-518.
• [4]Majeed A, Moser K, Carroll K: Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 2001, 86:284-288.
• [5]Fang MC, Stafford RS, Ruskin JN, Singer DE: National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004, 164:55-60.
• [6]Dewilde S, Carey IM, Emmas C, Richards N, Cook DG: Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006, 92:1064-1070.
• [7]Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J: Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004, 63:1059-1064.
• [8]Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS: The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151:297-305.
• [9]Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunso J, Tolstrup JS, Hansen PR, Gislason GH, et al.: Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011, 106:739-749.
• [10]Walley T, Mantgani A: The UK General Practice Research Database. Lancet 1997, 350:1097-1099.
• [11]Garcia Rodriguez LA, Perez GS: Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998, 45:419-425.
• [12]Jick H, Jick SS, Derby LE: Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991, 302:766-768.
• [13]Lawrenson R, Williams T, Farmer R: Clinical information for research; the use of general practice databases. J Public Health Med 1999, 21:299-304.
• [14]Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD: Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000, 49:591-596.
• [15]Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H: Validity of the general practice research database. Pharmacotherapy 2003, 23:686-689.
• [16]Suissa S: Novel approaches to pharmacoepidemiology study design and statistical analysis. In Pharmacoepidemiology. 4th edition. Edited by Chichester Strom B. John Wiley & Sons, England; 2005:811-829.
• [17]Essebag V, Platt RW, Abrahamowicz M, Pilote L: Comparison of nested case–control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005, 5:5. BioMed Central Full Text
• [18]Essebag V, Genest J, Suissa S, Pilote L: The nested case–control study in cardiology. Am Heart J 2003, 146:581-590.
• [19]Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE: Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003, 290:2685-2692.
• [20]Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
• [21]Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
• [22]Birman-Deych E, Radford MJ, Nilasena DS, Gage BF: Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006, 37:1070-1074.
• [23]Rietbrock S, Plumb JM, Gallagher AM, van Staa TP: How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost 2009, 101:527-534.
• [24]Gallagher AM, Rietbrock S, Plumb J, van Staa TP: Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008, 6:1500-1506.
• [25]Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE: Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010, 3:624-631.
• [26]White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW: Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167:239-245.